Pulmonary hypertension: Another light in the dark tunnel. Learning the lesson from cancer.
作者信息
Idrees Majdy
机构信息
Saudi Association for Pulmonary Hypertension, Pulmonary Division, Riyadh Military Hospital, Riyadh 11159, Saudi Arabia.
出版信息
Ann Thorac Med. 2013 Apr;8(2):69-70. doi: 10.4103/1817-1737.109813.
Abstract
摘要
相似文献
1
Pulmonary hypertension: Another light in the dark tunnel. Learning the lesson from cancer.
Ann Thorac Med. 2013 Apr;8(2):69-70. doi: 10.4103/1817-1737.109813.
2
The Impact of LED Color Rendering on the Dark Adaptation of Human Eyes at Tunnel Entrances.
Int J Environ Res Public Health. 2020 Feb 28;17(5):1566. doi: 10.3390/ijerph17051566.
3
Barlow's Repair: Light in the Dark Tunnel: A Case Report Could Omit 'Light in A Dark Tunnel'.
Med J Malaysia. 2015 Apr;70(2):106-7.
4
The Light at the End of the Long Pulmonary Hypertension Tunnel Brightens.
Am J Respir Crit Care Med. 2018 Sep 15;198(6):818-820. doi: 10.1164/rccm.201802-0325LE.
5
[Effects of different light-dark cycle on learning and memory in mice].
Space Med Med Eng (Beijing). 2004 Oct;17(5):381-2.
6
Time place learning and activity profile under constant light and constant dark in zebrafish (Danio rerio).
Behav Processes. 2017 May;138:49-57. doi: 10.1016/j.beproc.2017.02.015. Epub 2017 Feb 20.
7
Primary pulmonary hypertension: more light or more tunnel?
Ann Intern Med. 1981 Jun;94(6):815-7. doi: 10.7326/0003-4819-94-6-815.
8
Lesson Plans: Road Maps for the Active Learning Classroom.
J Nurs Educ. 2017 Nov 1;56(11):697-700. doi: 10.3928/01484834-20171020-12.
9
[Explaining Learning Disorders to Primary School Children: Evaluation of a Psychoeducational Lesson About Learning Disorders].
Prax Kinderpsychol Kinderpsychiatr. 2021 May;70(4):316-332. doi: 10.13109/prkk.2021.70.4.316.
10
Pulmonary capillary hemangiomatosis: a lesson learned.
Autops Case Rep. 2019 Aug 22;9(3):e2019111. doi: 10.4322/acr.2019.111. eCollection 2019 Jul-Sep.
引用本文的文献
1
Saudi experience in the management of pulmonary arterial hypertension; the outcome of PAH therapy with the exclusion of chronic parenteral prostacyclin.
Ann Thorac Med. 2015 Jul-Sep;10(3):204-11. doi: 10.4103/1817-1737.160842.
2
Pulmonary arterial hypertension in Saudi Arabia: Patients' clinical and physiological characteristics and hemodynamic parameters. A single center experience.
Ann Thorac Med. 2014 Oct;9(4):209-15. doi: 10.4103/1817-1737.140127.
3
Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Medical and surgical management for pulmonary arterial hypertension.
Ann Thorac Med. 2014 Jul;9(Suppl 1):S79-91. doi: 10.4103/1817-1737.134043.
4
Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: General management for pulmonary hypertension.
Ann Thorac Med. 2014 Jul;9(Suppl 1):S74-8. doi: 10.4103/1817-1737.134041.
5
Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Pulmonary arterial hypertension associated with connective tissue diseases.
Ann Thorac Med. 2014 Jul;9(Suppl 1):S26-37. doi: 10.4103/1817-1737.134016.
6
Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Intensive care management of pulmonary hypertension.
Ann Thorac Med. 2014 Jul;9(Suppl 1):S121-6. doi: 10.4103/1817-1737.134056.
7
Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Pulmonary hypertension in children.
Ann Thorac Med. 2014 Jul;9(Suppl 1):S113-20. doi: 10.4103/1817-1737.134053.
8
Saudi guidelines on the diagnosis and treatment of pulmonary hypertension: 2014 updates.
Ann Thorac Med. 2014 Jul;9(Suppl 1):S1-S15. doi: 10.4103/1817-1737.134006.
本文引用的文献
1
Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study.
Circulation. 2013 Mar 12;127(10):1128-38. doi: 10.1161/CIRCULATIONAHA.112.000765. Epub 2013 Feb 12.
2
Personalized medicine and inhibition of EGFR signaling in lung cancer.
N Engl J Med. 2009 Sep 3;361(10):1018-20. doi: 10.1056/NEJMe0905763. Epub 2009 Aug 19.
3
Updated clinical classification of pulmonary hypertension.
J Am Coll Cardiol. 2009 Jun 30;54(1 Suppl):S43-S54. doi: 10.1016/j.jacc.2009.04.012.
4
A meta-analysis of randomized controlled trials in pulmonary arterial hypertension.
Eur Heart J. 2009 Feb;30(4):394-403. doi: 10.1093/eurheartj/ehp022. Epub 2009 Jan 20.
5
Antiproliferative effect of sildenafil on human pulmonary artery smooth muscle cells.
Basic Res Cardiol. 2005 Mar;100(2):131-8. doi: 10.1007/s00395-004-0504-5. Epub 2004 Nov 24.
6
Pathologic assessment of vasculopathies in pulmonary hypertension.
J Am Coll Cardiol. 2004 Jun 16;43(12 Suppl S):25S-32S. doi: 10.1016/j.jacc.2004.02.033.
7
Cellular and molecular pathobiology of pulmonary arterial hypertension.
J Am Coll Cardiol. 2004 Jun 16;43(12 Suppl S):13S-24S. doi: 10.1016/j.jacc.2004.02.029.
8
The endothelin system in pulmonary arterial hypertension.
Cardiovasc Res. 2004 Feb 1;61(2):227-37. doi: 10.1016/j.cardiores.2003.11.026.
9
Endothelial dysfunction in pulmonary hypertension.
Circulation. 2004 Jan 20;109(2):159-65. doi: 10.1161/01.CIR.0000102381.57477.50.
10
Activation of tyrosine kinases in cancer.
Oncologist. 2003;8(6):531-8. doi: 10.1634/theoncologist.8-6-531.
Zotero 插件